Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Michael E. Williams, MD, of the University of Virginia School of Medicine, Charlottesville, VA, discusses the clinical development of venetoclax, a selective BCL-2 inhibitor, for the treatment of patients with non-Hodgkin lymphoma. Dr Williams focuses on a phase 1 clinical trial that was designed to determine the optimal dosing scheme for the combination of venetoclax and ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Share this video  
Similar topics